Login to Your Account


Vital Therapies prices below range as biotech IPOs show growing fatigue

By Marie Powers
Staff Writer

Thursday, April 17, 2014

The good news for Vital Therapies Inc. is that the company managed to eke out its initial public offering (IPO) despite the recent selloff in biotechnology stocks. The bad news is that Vital, like two other April graduates, slashed its price to get out the door. The San Diego-based firm raised $54 million, with most of the proceeds slated to fund late-stage trials of Elad, its human cell-based bio-artificial liver system.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription